These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 36854991)

  • 1. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children and Young Adults With Recently Diagnosed Type 1 Diabetes.
    Lee JB; Zhou W; Xu Z; Hedrick JA; Leu JH
    J Clin Pharmacol; 2023 Jun; 63(6):721-731. PubMed ID: 36854991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
    J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-Year Follow-up From the T1GER Study: Continued Off-Therapy Metabolic Improvements in Children and Young Adults With New-Onset T1D Treated With Golimumab and Characterization of Responders.
    Rigby MR; Hayes B; Li Y; Vercruysse F; Hedrick JA; Quattrin T
    Diabetes Care; 2023 Mar; 46(3):561-569. PubMed ID: 36576974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population Pharmacokinetics and Exposure-Response Modeling of Golimumab in Adults With Moderately to Severely Active Ulcerative Colitis.
    Adedokun OJ; Xu Z; Liao S; Strauss R; Reinisch W; Feagan BG; Sandborn WJ
    Clin Ther; 2020 Jan; 42(1):157-174.e4. PubMed ID: 31982148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
    Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
    N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous Golimumab in Patients with Polyarticular Juvenile Idiopathic Arthritis and Juvenile Psoriatic Arthritis and Subcutaneous Ustekinumab in Patients with Juvenile Psoriatic Arthritis: Extrapolation of Data from Studies in Adults and Adjacent Pediatric Populations.
    Leu JH; Shiff NJ; Clark M; Bensley K; Lomax KG; Berezny K; Nelson RM; Zhou H; Xu Z
    Paediatr Drugs; 2022 Nov; 24(6):699-714. PubMed ID: 36171515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetics of golimumab in patients with ankylosing spondylitis: impact of body weight and immunogenicity.
    Xu ZH; Lee H; Vu T; Hu C; Yan H; Baker D; Hsu B; Pendley C; Wagner C; Davis HM; Zhou H
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):596-607. PubMed ID: 20860913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis.
    Xu Z; Vu T; Lee H; Hu C; Ling J; Yan H; Baker D; Beutler A; Pendley C; Wagner C; Davis HM; Zhou H
    J Clin Pharmacol; 2009 Sep; 49(9):1056-70. PubMed ID: 19617465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis.
    Ruperto N; Brunner HI; Pacheco-Tena C; Louw I; Vega-Cornejo G; Spindler AJ; Kingsbury DJ; Schmeling H; Borzutzky A; Cuttica R; Inman CJ; Malievskiy V; Scott C; Keltsev V; Terreri MT; Viola DO; Xavier RM; Fernandes TAP; Velázquez MDRM; Henrickson M; Clark MB; Bensley KA; Li X; Lo KH; Leu JH; Hsu CH; Hsia EC; Xu Z; Martini A; Lovell DJ;
    Rheumatology (Oxford); 2021 Oct; 60(10):4495-4507. PubMed ID: 33493312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial.
    Brunner HI; Ruperto N; Tzaribachev N; Horneff G; Chasnyk VG; Panaviene V; Abud-Mendoza C; Reiff A; Alexeeva E; Rubio-Pérez N; Keltsev V; Kingsbury DJ; Del Rocio Maldonado Velázquez M; Nikishina I; Silverman ED; Joos R; Smolewska E; Bandeira M; Minden K; van Royen-Kerkhof A; Emminger W; Foeldvari I; Lauwerys BR; Sztajnbok F; Gilmer KE; Xu Z; Leu JH; Kim L; Lamberth SL; Loza MJ; Lovell DJ; Martini A;
    Ann Rheum Dis; 2018 Jan; 77(1):21-29. PubMed ID: 28507219
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Population Pharmacokinetic and Exposure-Response Model of Golimumab for Targeting Endoscopic Remission in Patients With Ulcerative Colitis.
    Dreesen E; Kantasiripitak W; Detrez I; Stefanović S; Vermeire S; Ferrante M; Bouillon T; Drobne D; Gils A
    Inflamm Bowel Dis; 2020 Mar; 26(4):570-580. PubMed ID: 31372650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Exposure-response Relationship of Golimumab in Patients with Moderately-to-Severely Active Ulcerative Colitis: Results from Phase 2/3 PURSUIT Induction and Maintenance Studies.
    Adedokun OJ; Xu Z; Marano CW; Strauss R; Zhang H; Johanns J; Zhou H; Davis HM; Reinisch W; Feagan BG; Rutgeerts P; Sandborn WJ
    J Crohns Colitis; 2017 Jan; 11(1):35-46. PubMed ID: 27440869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic and Exposure-Response Model Simulations: Predicted Exposure and Efficacy for Maintenance Doses of Intravenous Golimumab Every 6 or 8 Weeks in Patients With Moderately to Severely Active Rheumatoid Arthritis.
    Lee JB; Broadwell A; Fan Y; Hu C; Adedokun OJ; Chakravarty SD; Zhou H; Xu Z; Leu JH
    Clin Ther; 2022 Mar; 44(3):457-464.e2. PubMed ID: 35183373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and Pharmacodynamics of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis.
    Sun H; Van LM; Floch D; Jiang X; Klein UR; Abrams K; Sunkara G
    J Clin Pharmacol; 2016 Dec; 56(12):1516-1527. PubMed ID: 27119439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis.
    Gandhi Y; Passarell JA; Roy A; Murthy B
    J Clin Pharmacol; 2021 May; 61(5):688-699. PubMed ID: 33284480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and safety of golimumab in healthy Chinese subjects following a single subcutaneous administration in a randomized phase I trial.
    Zhuang Y; Lyn S; Lv Y; Xu Z; Bouman-Thio E; Masterson T; Ford JA; Keen M; Petty KJ; Davis HM; Zhou H
    Clin Drug Investig; 2013 Nov; 33(11):795-800. PubMed ID: 23975656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of racial differences in the pharmacokinetics of subcutaneous golimumab in healthy Japanese and Caucasian male subjects.
    Ling J; Lyn S; Xu Z; Achira M; Bouman-Thio E; Shishido A; Ford J; Shankar G; Wagner C; Kim KT; Davis HM; Zhou H
    J Clin Pharmacol; 2010 Jul; 50(7):792-802. PubMed ID: 20133508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of sifalimumab, an investigational anti-interferon-α monoclonal antibody, in systemic lupus erythematosus.
    Narwal R; Roskos LK; Robbie GJ
    Clin Pharmacokinet; 2013 Nov; 52(11):1017-27. PubMed ID: 23754736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.